DHR earnings call for the period ending December 31, 2019.
News & Analysis: Danaher
Danaher will close its purchase of GE’s biopharma unit in the first quarter of 2020.
The company had a great 2019 and looks well set for 2020, too.
These stocks could help investors deal with varying recessionary scenarios.
The company completed another impressive year of execution, and the agreement to buy GE's biopharma business looks like a great deal for shareholders.
The latest information confirms that Danaher's purchase of GE's biopharma business will be value-enhancing.
A rundown of what investments worked in the sector in 2019, plus commentary on their prospects in 2020.
Assuming the economy avoids a protracted slowdown next year, these companies' catalysts could deliver strong gains for investors.
These four CEOs' successes and failures have shaped how industrial businesses are run and how people invest in them.
Here are three stock picks from one of the best fund managers in the world.